An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia
Open accessAbstract
OBJECTIVE: Schizophrenia is a mental disorder characterized by severe cognitive impairment. Accumulating evidence suggests a role for oxidative stress in the pathophysiology of schizophrenia. Sulforaphane (SFN) extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. In this study, we attempted to evaluate the effect of SFN on cognitive impairment in medicated patients with schizophrenia. METHODS: We recruited a total of 10 outpatients with schizophrenia, all of whom gave informed consent. Participants took 3 tablets of SFN, consisting of 30 mg of SFN-glucosinolate per day, for 8 weeks. Clinical symptoms using the Positive and Negative Syndrome Scale (PANSS) and cognitive function using the Japanese version of CogState battery were evaluated at the beginning of the study and at week 8. RESULTS: A total of 7 patients completed the trial. The mean score in the Accuracy component of the One Card Learning Task increased significantly after the trial. However, we detected no other significant changes in participants. CONCLUSIONS: This result suggests that SFN has the potential to improve cognitive function in patients with schizophrenia.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
NFE2L2 activators promote neuronal resistance to oxidative stress via non-cell-autonomous mechanisms involving NFE2L2 activation in astrocytes, including human astrocytes.
“NFE2L2 activators promote neuronal resistance to oxidative stress via non cell-autonomous mechanisms involving NF22L2 activation in astrocytes, including human astrocytes 82,108”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [108]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,841 · see citing works
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010042 · Cited by 2,342 · see citing works
The clinical global impressions scale: applying a research tool in clinical practice.
Busner, J., & Targum, S. D. (2007) · PubMed Central · Cited by 1,952 · see citing works
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,022 · see citing works
Cognitive Impairment in Schizophrenia Is the Core of the Disorder
Elvevag, B., & Goldberg, T. E. (2000) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v14.i1.10 · Cited by 835 · cited 1× · see citing works
“62 pISSN 1738-1088 / eISSN 2093-4327 Clinical Psychopharmacology and Neuroscience 2015;13(1):62-67 Copyrightc 2015, Korean College of Neuropsychopharmacology”
BackgroundCognitive Impairment and Functional Outcome in Schizophrenia and Bipolar Disorder
Green, M. F. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.1006e12 · Cited by 794 · see citing works
Fahey, J. W., Haristoy, X., Dolan, P. M., Kensler, T. W., Scholtus, I., Stephenson, K. K., Talalay, P., & Lozniewski, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112203099 · Cited by 794 · see citing works
Cognition in schizophrenia: core psychological and neural mechanisms
Barch, D. M., & Ceaser, A. E. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.11.015 · Cited by 752 · see citing works
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
Kern, R. S., Nuechterlein, K. H., Green, M. F., Baade, L. E., Fenton, W. S., Gold, J. M., Keefe, R. S. E., Mesholam-Gately, R., Mintz, J., Seidman, L. J., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010043 · Cited by 744 · see citing works
Molecular basis for chemoprevention by sulforaphane: a comprehensive review
Juge, N., Mithen, R. F., & Τράκα, Μ. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6484-5 · Cited by 696 · see citing works
Maruff, P., Thomas, E., Cysique, L., Brew, B., Collie, A., Snyder, P., & Pietrzak, R. H. (2009) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acp010 · Cited by 635 · see citing works
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 617 · see citing works
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552 · see citing works
Oxidative stress in schizophrenia: An integrated approach
Bitanihirwe, B. K. Y., & Woo, T.-U. W. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.008 · Cited by 474 · see citing works
Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis
Green, M. J., Matheson, S. L., Shepherd, A., Weickert, C. S., & Carr, V. J. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.88 · Cited by 453 · see citing works
Status of computerized cognitive testing in aging: a systematic review
Wild, K., Howieson, D., Webbe, F., Seelye, A., & Kaye, J. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.07.003 · Cited by 436 · see citing works
Falleti, M. G., Maruff, P. T., Collie, A., & Darby, D. (2006) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390500205718 · Cited by 424 · see citing works
Hashimoto, K. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02113.x · Cited by 388 · see citing works
Self-citationPeet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00083-9 · Cited by 329 · see citing works
Peet, M., & Horrobin, D. F. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00048-6 · Cited by 329 · see citing works
Fenton, W. S., Dickerson, F., Boronow, J. J., Hibbeln, J. R., & Knable, M. B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2071 · Cited by 322 · see citing works
Emsley, R. A., Myburgh, C., Oosthuizen, P. P., & van Rensburg, S. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.9.1596 · Cited by 306 · see citing works
Robinson, D. G., Woerner, M. G., Alvir, J. M. J., Bilder, R. M., Hinrichsen, G. A., & Lieberman, J. A. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00312-7 · Cited by 290 · see citing works
Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View
Yao, J. K., & Keshavan, M. S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3603 · Cited by 285 · see citing works
Oxidative Damage and Schizophrenia
Yao, J. K., Reddy, R. D., & van Kammen, D. P. (2001) · CNS Drugs · doi:10.2165/00023210-200115040-00004 · Cited by 280 · see citing works
Yoshida, T., Ishikawa, M., Niitsu, T., Nakazato, M., Watanabe, H., Shiraishi, T., Shiina, A., Hashimoto, T., Kanahara, N., Hasegawa, T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042676 · Cited by 278 · see citing works
Self-citationFredrickson, J., Maruff, P. T., Woodward, M., Moore, L., Fredrickson, A., Sach, J., & Darby, D. (2009) · Neuroepidemiology · doi:10.1159/000264823 · Cited by 236 · see citing works
Mahadik, S. P., Evans, D. R., & Lal, H. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00181-0 · Cited by 229 · see citing works
Add-on Treatment of Benzoate for Schizophrenia
Lane, H., Lin, C., Green, M. F., Hellemann, G., Huang, C., Chen, P., Tun, R., Chang, Y.-C., & Tsai, G. E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2159 · Cited by 229 · see citing works
Hashimoto, K. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.09.001 · Cited by 208 · see citing works
Self-citationPietrzak, R. H., Olver, J. S., Norman, T. R., Piškulić, D., Maruff, P. T., & Snyder, P. J. (2009) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390802592458 · Cited by 202 · see citing works
Lieberman, J. A., Dunbar, G. C., Segreti, A. C., Girgis, R. R., Seoane, F., Beaver, J. S., Duan, N., & Hosford, D. A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.259 · Cited by 176 · see citing works
Partial compliance in schizophrenia and the impact on patient outcomes
Llorca, P. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.07.012 · Cited by 163 · see citing works
Lim, Y. Y., Ellis, K. A., Harrington, K., Ames, D. J., Martins, R. N., Masters, C. L., Rowe, C. C., Savage, G. R., Szoeke, C. E. I., Darby, D., et al. (2012) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2011.643227 · Cited by 145 · see citing works
Keefe, R. S. E., Buchanan, R. W., Marder, S. R., Schooler, N. R., Dugar, A., Zivkov, M., & Stewart, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr153 · Cited by 138 · see citing works
Cole, W. R., Arrieux, J. P., Schwab, K. A., Ivins, B. J., Qashu, F. M., & Lewis, S. C. (2013) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/act040 · Cited by 124 · see citing works
Is Altered BDNF Biosynthesis a General Feature in Patients with Cognitive Dysfunctions?
Carlino, D., Vanna, M. D., & Tongiorgi, E. (2012) · The Neuroscientist · doi:10.1177/1073858412469444 · Cited by 113 · see citing works
Lim, Y. Y., Jaeger, J., Harrington, K., Ashwood, T., Ellis, K. A., Stöffler, A., Szoeke, C. E. I., Lachovitzki, R., Martins, R. N., Villemagne, V. L., et al. (2013) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/act021 · Cited by 111 · see citing works
BDNF–TrkB signaling and neuroprotection in schizophrenia
Pandya, C. D., Kutiyanawalla, A., & Pillai, A. (2012) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2012.08.010 · Cited by 110 · see citing works
Gubert, C., Stertz, L., Pfaffenseller, B., Panizzutti, B., Rezin, G. T., Massuda, R., STRECK, E. L., Gama, C. S., Kapczinski, F. P., & Kunz, M. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.06.018 · Cited by 108 · see citing works
Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases
Niitsu, T., Iyo, M., & Hashimoto, K. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799436476 · Cited by 99 · see citing works
Self-citationA randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
Shiina, A., Shirayama, Y., Niitsu, T., Hashimoto, T., Yoshida, T., Hasegawa, T., Haraguchi, T., Kanahara, N., Shiraishi, T., Fujisaki, M., et al. (2010) · Annals of General Psychiatry · doi:10.1186/1744-859x-9-27 · Cited by 94 · see citing works
Self-citationZhang, X. Y., Zhou, D. F., Zhang, P. Y., Wu, G. Y., Su, J. M., & Cao, L. Y. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1107 · Cited by 90 · see citing works
Chengappa, K. N. R., Turkin, S. R., DeSanti, S., Bowie, C. R., Brar, J. S., Schlicht, P. J., Murphy, S. L., Hetrick, M. L., Bilder, R. M., & Fleet, D. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.10.001 · Cited by 86 · see citing works
Intraindividual cognitive decline using a brief computerized cognitive screening test
Darby, D., Pietrzak, R. H., Fredrickson, J., Woodward, M., Moore, L., Fredrickson, A., Sach, J., & Maruff, P. T. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.12.009 · Cited by 83 · see citing works
Reliability of Repeated Cognitive Assessment of Dementia Using a Brief Computerized Battery
Hammers, D. B., Spurgeon, E., Ryan, K. A., Persad, C. C., Heidebrink, J. L., Barbas, N. R., Albin, R. L., Frey, K. A., Darby, D., & Giordani, B. (2011) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317511411907 · Cited by 81 · see citing works
Murthy, N. V., Mahncke, H. W., Wexler, B. E., Maruff, P. T., Inamdar, A., Zucchetto, M., Lund, J., Shabbir, S., Shergill, S. S., Keshavan, M. S., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.01.042 · Cited by 79 · see citing works
Huerta‐Ramos, E., Iniesta, R., Ochoa, S., Cobo, J., Miquel, E., Roca, M., Serrano‐Blanco, A., Teba, F., & Usall, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.11.012 · Cited by 77 · see citing works
A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia
Nurjono, M., Lee, J., & Chong, S. A. (2012) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2012.10.2.61 · Cited by 75 · see citing works
Plasma total antioxidant status and cognitive impairments in schizophrenia
Zhang, X., Chen, D. C., Xiu, M. H., Tang, W., Zhang, F., Liu, L., Chen, Y., Liu, J., Yao, J. K., Kosten, T. A., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.04.009 · Cited by 70 · see citing works
Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia
Sumiyoshi, T., Higuchi, Y., & Uehara, T. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00140 · Cited by 62 · see citing works
Shirai, Y., Fujita, Y., & Hashimoto, K. (2012) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2012.10.2.94 · Cited by 54 · see citing works
Self-citationPietrzak, R. H., Snyder, P. J., Jackson, C. E., et al. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.998 · Cited by 50 · see citing works
Chen, H., Wu, J., Zhang, J., Fujita, Y., Ishima, T., Iyo, M., & Hashimoto, K. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2619-3 · Cited by 49 · see citing works
Self-citationYoshida, T., Suga, M., Arima, K., Muranaka, Y., Tanaka, T., Eguchi, S., Lin, C., Yoshida, S., Ishikawa, M., Higuchi, Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020469 · Cited by 43 · see citing works
Self-citationTreating Impaired Cognition in Schizophrenia
Ibrahim, H. M., & Tamminga, C. A. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784772 · Cited by 40 · see citing works
Antioxidant Therapeutics for Schizophrenia
Reddy, R. D., & Reddy, R. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3571 · Cited by 40 · see citing works
Wu, J. Q., Chen, D. C., Tan, Y., Tan, S., Wang, Z. R., Xiu, M. H., Yang, F. D., & Zhang, X. Y. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.11.010 · Cited by 38 · see citing works
A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia
Niitsu, T., Fujisaki, M., Shiina, A., Yoshida, T., Hasegawa, T., Kanahara, N., Hashimoto, T., Shiraishi, T., Fukami, G., Nakazato, M., et al. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182664cfc · Cited by 38 · see citing works
Self-citationZhang, X. Y., Chen, D. C., Xiu, M. H., Tan, Y. L., Yang, F. D., Zhang, L. Y., Zhang, L. Y., Haile, C. N., & Kosten, T. R. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.03.014 · Cited by 24 · see citing works
Sulforaphane protects SK‐N‐SH cells against antipsychotic‐induced oxidative stress
Mas, S., Gassó, P., Trias, G., Bernardo, M., & Lafuente, A. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00988.x · Cited by 22 · see citing works
Saruwatari, J., Yasui‐Furukori, N., Kamihashi, R., Yoshimori, Y., Oniki, K., Tsuchimine, S., Noai, M., Sato, Y., Nakagami, T., Sugawara, N., et al. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s52585 · Cited by 18 · see citing works
Kim, Q., Conus, P., & Cuénod, M. (2010) · Lifestyle Genomics · doi:10.1159/000324366 · Cited by 13 · see citing works
Ichimura, S., Ohira, T., Kobayashi, M., Kano, T., Akiyama, T., Orii, M., FUKUNAGA, A., & Kawase, T. (2010) · Neurologia medico-chirurgica · doi:10.2176/nmc.50.441 · Cited by 11 · see citing works
Do, K., Conus, P., & Cuenod, M. (2010) · World Review of Nutrition and Dietetics · doi:10.1159/000314518 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis
Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304 · see citing works
Yao, W., Zhang, J.-C., Ishima, T., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., Wu, J., Suganuma, H., et al. (2016) · Scientific Reports · doi:10.1038/srep30659 · Cited by 154 · see citing works
Self-citationEssential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and Future Perspective
Hashimoto, K. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01182 · Cited by 98 · see citing works
Pharmacology and Clinical Drug Candidates in Redox Medicine
Dao, V. T.-V., Casas, A. I., Maghzal, G. J., Seredenina, T., Kaludercic, N., Robledinos-Anton, N., Di Lisa, F., Stocker, R., Ghezzi, P., Jaquet, V., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6430 · Cited by 88 · see citing works
Keap1-Nrf2 signaling pathway confers resilience versus susceptibility to inescapable electric stress
Zhang, J.-C., Yao, W., Dong, C., Han, M., Shirayama, Y., & Hashimoto, K. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0848-0 · Cited by 66 · see citing works
Self-citation
- Authors
- Shiina, A., Kanahara, N., Sasaki, T., Oda, Y., Hashimoto, T., Hasegawa, T., Yoshida, T., Iyo, M., & Hashimoto, K.
- Affiliations
- Chiba University (JP)
- Chiba University Hospital (JP)
- Kisarazu Hospital (JP)
- Corresponding author
- Shiina, Akihiro
- ORCID
- Venue
- Clinical Psychopharmacology and Neuroscience
- Published
- 2015-04-30
- Volume
- 13
- Issue
- 1
- Pages
- 62-67
- ISSN
- 1738-1088 (ISSN-L)
- 2093-4327
- PMC
- PMC4423155
- OpenAlex
- W2334107882
- Cited by
- 107
- References
- 66
- Citations by year
- 2026: 2 · 2025: 13 · 2024: 8 · 2023: 6 · 2022: 14 · 2021: 22 · 2020: 9 · 2019: 7 · 2018: 11 · 2017: 6 · 2016: 6 · 2015: 3
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Clinical Psychopharmacology and Neuroscience (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Keywords
- sulforaphane, broccoli sprout extract, schizophrenia, cognitive impairment, oxidative stress, antioxidant activity, anti-inflammatory activity, cognitive function, PANSS, CogState
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
